Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Smith Thomas BOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-995Price:$36.76
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Dreyer ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-664Price:$37.15
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Dreyer ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,336Price:$36.38
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Tupper ColleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-9,453Price:$33.70
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Tupper ColleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-16,868Price:$33.70
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Tupper ColleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,856Price:--
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Tupper ColleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,600Price:--
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Dreyer ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-10,145Price:$33.70
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Dreyer ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-19,545Price:$33.70
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Dreyer ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:32,286Price:--
Filings by filing date
-
Feb 29, 2024 (filed on Mar 04, 2024)Insider Name:Smith Thomas BOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-995Price:$36.76
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Dreyer ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-664Price:$37.15
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Dreyer ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,336Price:$36.38
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Tupper ColleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-9,453Price:$33.70
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Tupper ColleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-16,868Price:$33.70
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Tupper ColleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:30,856Price:--
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Tupper ColleenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,600Price:--
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Dreyer ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-10,145Price:$33.70
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Dreyer ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-19,545Price:$33.70
-
Feb 12, 2024 (filed on Feb 14, 2024)Insider Name:Dreyer ScottOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:32,286Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Technology Center Dr STOUGHTON MA 02072-4710 |
Tel: | N/A |
Website: | https://www.collegiumpharma.com |
IR: | See website |
Key People | ||
Joseph J. Ciaffoni President, Chief Executive Officer, Director | Colleen Tupper Chief Financial Officer, Executive Vice President | Shirley R. Kuhlmann Executive Vice President, Chief Administrative Officer, General Counsel, Secretary |
Scott Dreyer Executive Vice President, Chief Commercial Officer | Thomas B. Smith Executive Vice President, Chief Medical Officer |
Business Overview |
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. |
Financial Overview |
For the fiscal year ended 31 December 2023, Collegium Pharmaceutical Inc revenues increased 22% to $566.8M. Net income totaled $48.2M vs. loss of $25M. Revenues reflect Belbuca segment increase of 44% to $182.1M, Xtampza segment increase of 28% to $177.4M. Net Income reflects Acquisition Related expense decrease from $31.3M (expense) to $0K, Interest Income increase from $1M to $15.6M (income). |
Employees: | 197 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,517M as of Dec 31, 2023 |
Annual revenue (TTM): | $566.77M as of Dec 31, 2023 |
EBITDA (TTM): | $324.72M as of Dec 31, 2023 |
Net annual income (TTM): | $48.16M as of Dec 31, 2023 |
Free cash flow (TTM): | $274.29M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $356.62M as of Dec 31, 2023 |
Shares outstanding: | 32,705,747 as of Mar 27, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |